SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has been featured in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the treatment of obesity, type 2 diabetes and related metabolic conditions.
The GLP-1 drug class has seen explosive growth, with blockbuster drugs like Ozempic and Wegovy generating billions in revenue. However, tolerability issues and the need for injectable delivery remain significant barriers for patients. GEP-44 aims to address these challenges. According to the editorial, the triple agonist mechanism targets multiple pathways, potentially offering improved weight loss and glycemic control while reducing side effects. Additionally, the peptide may enable non-injectable delivery routes, such as oral or nasal administration, which could dramatically increase patient compliance and market reach.
SureNano Science, a Canadian life sciences company, is transitioning from its initial business of distributing the SureNano™ surfactant for nanoemulsions to becoming a pharmaceutical-focused company through the advancement of GEP-44. The company acquired GlucaPharm Inc. in early 2026, securing the patented peptide candidate. “The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant… The Company is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease,” the press release states.
The editorial’s focus on GEP-44 underscores the growing interest in next-generation GLP-1 therapies that can overcome current limitations. For investors, the feature placement on BioMedWire may increase visibility for SureNano Science. The company’s stock trades on the Canadian Securities Exchange and OTCQB under the symbols SURE and SURNF, respectively. More information is available in the company’s newsroom at https://ibn.fm/SURNF.
BioMedWire is a specialized communications platform focused on the biotech, biomedical, and life sciences sectors. The full press release can be viewed at https://ibn.fm/9zCgz. As the GLP-1 market continues to expand, innovations like GEP-44 could play a crucial role in shaping the future of obesity and diabetes treatment, offering new hope for patients and new opportunities for pharmaceutical companies.
